Broadcast Date: February 23, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
With gene therapy rapidly shifting from orphan to prevalent indications, the demand for viral vectors is surging—especially for adeno-associated virus (AAV). Yet the industry is still primarily operating on the legacy process of transient transfection, which requires large amounts of expensive GMP-grade DNA while carrying only limited scale-up potential. Nobody would consider such a process for industrial antibody production, but it is still the norm for AAV. The ELEVECTA
platform of inducible stable AAV producer cell lines solves this issue.
In this GEN webinar, we will dive deeply into the ELEVECTA technology to better understand how you can produce high-titer and high-quality AAV vectors as easily as antibodies.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Produced with support from:
VP Technology Development
Cevec Pharmaceuticals GmbH – Now Part of Cytiva
The post Novel AAV Manufacturing Platform for Inducible Stable Producer Cells appeared first on GEN – Genetic Engineering and Biotechnology News.
